Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

masofaniten

An orally bioavailable, second-generation inhibitor of the N-terminal domain (NTD) of androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, masofaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells. Masofaniten may be more active and metabolically stable than first-generation AR NTD inhibitors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:androgen receptor inhibitor EPI-7386
AR inhibitor EPI-7386
Code name:EPI 7386
EPI-7386
EPI7386
Chemical structure:methanesulfonamide, N-(4-((4-(1-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)-1-methylethyl)phenoxy)methyl)-2-pyrimidinyl)-
N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl)propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search